877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models
Main Authors: | Matthew King, Dmitry Gabrilovich, Simon Barry, Mark Cobbold, Viia Valge-Archer, Adina Hughes, Elizabeth Hardaker, Alison Peter, Anisha Solanki, Lukasz Magiera, Gozde Kar, Stephen Fawell, Ankur Karmokar, Marta Milo, Chrysiis Michaloglou, Ricardo Miragaia, Sara Talbot, Carolyn Lam, Daniel Sutton, Scott Hoffmann, Larissa Carnevalli, Zena Wilson, Alan Lau |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
by: Elizabeth L. Hardaker, et al.
Published: (2024-02-01) -
957 The ATR-inhibitor ceralasertib modulates the tumor microenvironment and improves the effect of anti-PDL1 by activating type I IFN pathway
by: Dmitry Gabrilovich, et al.
Published: (2023-11-01) -
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
by: Anna D. Staniszewska, et al.
Published: (2022-12-01) -
886 In vitro study of the effects of ceralasertib (AZD6738) on the tumor microenvironment cell populations
by: Gemma Jones, et al.
Published: (2023-11-01) -
P758: INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY
by: A. Brunner, et al.
Published: (2022-06-01)